Open AccessRisk of Recurrent Helicobacter pylori Infection 1 Year After Initial Eradication Therapy in 7 Latin American Communities
Author(s) -
Douglas R. Morgan,
Javier Torres,
Rachael Sexton,
Rolando Herrero,
Eduardo Salazar-Martínez,
E. Robert Greenberg,
Luis Eduardo Bravo,
Ricardo L. Domínguez,
Catterina Ferreccio,
Eduardo LazcanoPonce,
María Mercedes MezaMontenegro,
Edgar M. Peña-Galo,
Rodolfo Peña,
Pelayo Correa,
Marı́a Elena Martı́nez,
William D. Chey,
Manuel Valdivieso,
Garnet L. Anderson,
Gary E. Goodman,
John J. Crowley,
Laurence H. Baker
Publication year - 2013
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2013.311
Subject(s) - lansoprazole , medicine , clarithromycin , helicobacter pylori , urea breath test , amoxicillin , metronidazole , gastroenterology , randomized controlled trial , concomitant , randomization , antibiotics , helicobacter pylori infection , biology , microbiology and biotechnology
The long-term effectiveness of Helicobacter pylori eradication programs for preventing gastric cancer will depend on recurrence risk and individual and community factors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom